NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC 50 =3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP. In Vitro NVX-207 induces cell death via apoptosis. NVX-207 has a high cytotoxicity with IC 50 values ranging from 7.6-8.5 µM, in the three analyzed malignant glioma cell lines. NVX-207 leads to PARP cleavage and to a decrease in Survivin expression levels under normoxic and hypoxic conditions. NVX-207 (20 µM) causes a significantly high rate of necrosis of glioma cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Intravenous application of NVX-207 in mice is well tolerated . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Assay Cytotoxic activities are evaluated using the Sulforhodamine-B (SRB) assay. Exponentially growing cells are seeded into 96-well plates at cell densities to prevent confluence for 96 h. After 24 h, the cells are treated using a dilution series of the compounds for 72 h under normoxic or hypoxic conditions. After treatment, the adherent cells are fixed using 10% TCA at 4°C for 1 h; the cells are washed with ice-cold water and are dyed using 100 µL of 4.4% SRB solution for 10 min. After staining, the plates are washed with 1% acetic acid and air-dried overnight. Three hundred microliters of 20 mM Tris base solution is added, and the absorbance is measured at 540 nm using a 96-well plate reader. The IC 50 values indicate the concentrations of the compound that cause 50% cell inhibition. The data are obtained in three independent experiments. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid